Seeking Alpha

Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S.

GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...
GEN

Protein Microarray Market Scope Broadens

Focused Protein Profiling Strategies and Reverse-phase Arrays Drive Growth Multiplexed protein measurements using protein microarrays have several promising applications in drug discovery and clinical ...
Seeking Alpha

Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant ...

Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (THER) (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse ...
ascopubs.org

Interim analysis examining the feasibility of incorporating laser microdissection enrichment of tumor specimens and reverse phase protein array analysis with next generation ...

Comprehensive clinical tumor RNA sequencing for children with cancer.
ascopubs.org

Utilization of germline testing in patients with early-onset pancreatic cancer (EOPC).

Proteomic quantification of HER-2 abundance and activation in pancreatic ductal adenocarcinoma tumor specimens using reverse phase protein array. Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 ...